MedTrace Logo

Docetaxel in Node Positive Adjuvant Breast Cancer

NCT00688740 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1491

Last updated 2011-02-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable breast cancer patients with positive axillary lymph nodes.

Conditions

Interventions

DRUG

Docetaxel

intravenous

DRUG

5-fluorouracil

intravenous

DRUG

Doxorubicin

intravenous

DRUG

Cyclophosphamide

intravenous

Sponsors & Collaborators

  • Cancer International Research Group (CIRG)

    collaborator OTHER

  • Sanofi

    lead INDUSTRY

Principal Investigators

  • ICD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States
  • Argentina
  • Austria
  • Brazil
  • Canada
  • Czechia
  • Egypt
  • France
  • Germany
  • Greece
  • Hungary
  • Israel
  • Poland
  • Portugal
  • Slovakia
  • South Africa
  • Spain
  • Sweden
  • United Kingdom
  • Uruguay

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688740 on ClinicalTrials.gov